Pharsight

Definity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5585112 LANTHEUS MEDCL Method of preparing gas and gaseous precursor-filled microspheres
Dec, 2013

(10 years ago)

US5527521 LANTHEUS MEDCL Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
Feb, 2015

(9 years ago)

US6033645 LANTHEUS MEDCL Methods for diagnostic imaging by regulating the administration rate of a contrast agent
Jun, 2016

(7 years ago)

US8685441 LANTHEUS MEDCL Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jan, 2019

(5 years ago)

US9545457 LANTHEUS MEDCL Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jan, 2019

(5 years ago)

US8658205 LANTHEUS MEDCL Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jun, 2019

(4 years ago)

US10583207 LANTHEUS MEDCL Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

US11529431 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US9789210 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US11266750 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10583208 LANTHEUS MEDCL Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

US10588988 LANTHEUS MEDCL Methods and devices for preparation of ultrasound contrast agents
May, 2037

(13 years from now)

Definity is owned by Lantheus Medcl.

Definity contains Perflutren.

Definity has a total of 12 drug patents out of which 6 drug patents have expired.

Expired drug patents of Definity are:

  • US5585112
  • US5527521
  • US6033645
  • US8685441
  • US9545457
  • US8658205

Definity was authorised for market use on 31 July, 2001.

Definity is available in injectable;intravenous dosage forms.

Definity can be used as method of using the drug substance/drug product for ultrasound imaging.

The generics of Definity are possible to be released after 04 May, 2037.

Drugs and Companies using PERFLUTREN ingredient

Market Authorisation Date: 31 July, 2001

Treatment: Method of using the drug substance/drug product for ultrasound imaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

DEFINITY family patents

Family Patents